

Frank Balis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6280047/publications.pdf>

Version: 2024-02-01

148
papers

7,223
citations

41344

49
h-index

62596

80
g-index

148
all docs

148
docs citations

148
times ranked

7999
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-dependent reference intervals in children for the disialoganglioside, GD2, a circulating tumor biomarker for the childhood cancer, neuroblastoma. <i>Clinical Biochemistry</i> , 2022, 101, 1-4.	1.9	0
2	An enhanced recovery after surgery protocol in children who undergo nephrectomy for Wilms tumor safely shortens hospital stay. <i>Journal of Pediatric Surgery</i> , 2022, 57, 259-265.	1.6	7
3	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). <i>Clinical Cancer Research</i> , 2021, 27, 3543-3548.	7.0	59
4	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 807-815.	2.3	3
5	Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. <i>Journal of Circulating Biomarkers</i> , 2021, 10, 26-29.	1.3	2
6	The ganglioside G _{D2} as a circulating tumor biomarker for neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28031.	1.5	30
7	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 829-840.	2.3	22
8	Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma. <i>DNA and Cell Biology</i> , 2019, 38, 1143-1146.	1.9	1
9	Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine-based estimates of renal function. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27672.	1.5	4
10	A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS10066-TPS10066.	1.6	2
11	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. <i>Oncologist</i> , 2018, 23, 762-e79.	3.7	28
12	Case Report: Nephron-sparing Surgery in a Patient With Bilateral Multifocal Wilms Tumor. <i>Urology</i> , 2018, 119, 146-148.	1.0	2
13	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. <i>Oncologist</i> , 2018, 23, 52-61.	3.7	123
14	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , 2018, 24, 753-765.	7.0	26
15	Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27296.	1.5	32
16	G _{D2} as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10538-10538.	1.6	2
17	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26636.	1.5	23
18	First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 181-187.	2.3	28

#	ARTICLE	IF	CITATIONS
19	Pencil beam scanning proton therapy for treatment of the retroperitoneum after nephrectomy for Wilms tumor: A dosimetric comparison study. <i>Pediatric Blood and Cancer</i> , 2017, 64, 39-45.	1.5	22
20	Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology's Friends of Cancer Research Minimum Age Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3781-3787.	1.6	69
21	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10540-10540.	1.6	2
22	Effect of infusion duration on high-dose methotrexate (HDMTX) acute kidney injury (AKI).. <i>Journal of Clinical Oncology</i> , 2017, 35, e22013-e22013.	1.6	0
23	15-0600-Dr. Fox's response to letter to the editor. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1099-1100.	2.3	0
24	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 405-412.	2.3	24
25	Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2015, 2015, 3.	1.6	10
26	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 629-636.	1.5	43
27	Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1273-1283.	2.3	48
28	Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1047-1055.	2.3	34
29	Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1598-1602.	1.5	78
30	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-51: A report from the Children's Oncology Group (ANBL0621). <i>Pediatric Blood and Cancer</i> , 2014, 61, 990-996.	1.5	16
31	Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Neuro-Oncology</i> , 2014, 16, 707-718.	1.2	93
32	A Qualitative Study of Phase III Cancer Clinical Trial Enrollment Decision-Making: Perspectives from Adolescents, Young Adults, Caregivers, and Providers. <i>Journal of Adolescent and Young Adult Oncology</i> , 2014, 3, 3-11.	1.3	47
33	Prospective assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10053-10053.	1.6	0
34	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 472-480.	10.7	614
35	Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. <i>Pediatric Blood and Cancer</i> , 2013, 60, 396-401.	1.5	67
36	Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4239-4248.	7.0	136

#	ARTICLE	IF	CITATIONS
37	Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. <i>Cell Cycle</i> , 2012, 11, 963-973.	2.6	13
38	¹¹¹ In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E207-E212.	3.6	18
39	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 6011-6022.	7.0	103
40	A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®; ET-743) in children and adolescents with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 865-869.	1.5	25
41	The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 247-252.	2.3	3
42	The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. <i>Investigational New Drugs</i> , 2012, 30, 524-528.	2.6	20
43	A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. <i>Journal of Neuro-Oncology</i> , 2012, 106, 643-649.	2.9	70
44	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9500-9500.	1.6	29
45	Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9576-9576.	1.6	0
46	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 569-580.	7.0	149
47	Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium. <i>Journal of Clinical Oncology</i> , 2011, 29, 839-844.	1.6	100
48	Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1291-1297.	2.3	1
49	Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 226-233.	1.5	21
50	Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5982-5990.	7.0	10
51	Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 817-824.	2.3	74
52	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	2.3	16
53	Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. <i>Pediatric Blood and Cancer</i> , 2010, 54, 47-54.	1.5	22
54	A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5174-5181.	1.6	98

#	ARTICLE	IF	CITATIONS
55	Commentary. <i>Clinical Chemistry</i> , 2010, 56, 1795-1795.	3.2	0
56	Dexrazoxane as a Cardioprotectant in Children Receiving Anthracyclines. <i>Oncologist</i> , 2010, 15, 1220-1226.	3.7	21
57	Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 3979-3986.	1.6	130
58	Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2010, 16, 750-754.	7.0	41
59	Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary Endpoint. <i>Journal of the National Cancer Institute</i> , 2010, 102, 909-912.	6.3	15
60	Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas. <i>Clinical Cancer Research</i> , 2009, 15, 7361-7367.	7.0	38
61	A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. <i>Clinical Cancer Research</i> , 2009, 15, 3574-3582.	7.0	101
62	Sorafenib and Sunitinib. <i>Oncologist</i> , 2009, 14, 800-805.	3.7	52
63	The Legacy of Cancer Therapy in Children. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1105-1107.	6.3	4
64	Trabectedin. <i>Oncologist</i> , 2009, 14, 794-799.	3.7	14
65	Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 550-556.	1.6	20
66	Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 137-142.	2.3	21
67	Conformational Heterogeneity and Quasi-Static Self-Quenching in DNA Containing a Fluorescent Guanine Analogue, 3MI or 6MI. <i>Biochemistry</i> , 2009, 48, 8861-8868.	2.5	24
68	Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 355-361.	2.3	29
69	The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 387-392.	2.3	31
70	Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 433-437.	2.3	22
71	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	7.0	45
72	Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials. <i>Oncologist</i> , 2008, 13, 679-689.	3.7	54

#	ARTICLE	IF	CITATIONS
73	Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. <i>Blood</i> , 2008, 111, 566-573.	1.4	113
74	Concise Drug Reviews: Introducing a New Series. <i>Oncologist</i> , 2007, 12, 151-151.	3.7	0
75	Drug Therapy in Neonates and Pediatric Patients. , 2007, , 359-373.		3
76	Dose-Effect and Concentration-Effect Analysis. , 2007, , 289-300.		4
77	Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). <i>Pediatric Blood and Cancer</i> , 2007, 49, 250-255.	1.5	26
78	A phase 2 trial of all-trans-retinoic acid in combination with interferon- γ 2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. <i>Pediatric Blood and Cancer</i> , 2007, 49, 661-665.	1.5	39
79	Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 563-567.	2.3	5
80	Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2006, 24, 507-516.	1.6	139
81	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	7.0	45
82	Very high-dose methotrexate (33.6 g/m ²) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. <i>Leukemia and Lymphoma</i> , 2006, 47, 2488-2504.	1.3	39
83	A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. <i>Cancer</i> , 2005, 103, 1932-1938.	4.1	83
84	Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 7646-7653.	1.6	45
85	Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection. <i>Pediatrics</i> , 2005, 116, e846-e854.	2.1	82
86	Intrathecal Mafosfamide: A Preclinical Pharmacology and Phase I Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 1555-1563.	1.6	62
87	RESPONSE: Re: Treatment of Accidental Intrathecal Methotrexate Overdose. <i>Journal of the National Cancer Institute</i> , 2005, 97, 610-611.	6.3	2
88	Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates. <i>Clinical Cancer Research</i> , 2005, 11, 1669-1674.	7.0	81
89	The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2005, 583, 105-119.	1.7	8
90	Loss of Smad3 in Acute T-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 552-559.	27.0	153

#	ARTICLE	IF	CITATIONS
91	A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4724-4733.	7.0	69
92	Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1557-1559.	6.3	60
93	Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates. <i>Clinical Cancer Research</i> , 2004, 10, 2525-2529.	7.0	63
94	High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. <i>Cancer</i> , 2004, 100, 2222-2232.	4.1	271
95	Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 124-129.	3.2	56
96	Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. <i>Journal of Neuro-Oncology</i> , 2003, 61, 203-207.	2.9	125
97	Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 417-423.	2.3	4
98	Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. <i>Journal of Clinical Oncology</i> , 2003, 21, 1866-1873.	1.6	127
99	Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic Meningitis. <i>Journal of Clinical Oncology</i> , 2003, 21, 143-147.	1.6	93
100	Evaluation and Treatment of Fever in the Non-Neutropenic Child With Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 606-612.	0.6	17
101	Clinical Trial Design for Target-Based Therapy. <i>Oncologist</i> , 2002, 7, 401-409.	3.7	145
102	Zidovudine Concentration in Brain Extracellular Fluid Measured by Microdialysis: Steady-State and Transient Results in Rhesus Monkey. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 1003-1011.	2.5	33
103	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> , 2002, 99, 2685-2693.	1.4	292
104	Mixing during intravertebral arterial infusions in an in vitro model. <i>Journal of Neuro-Oncology</i> , 2002, 58, 95-106.	2.9	17
105	Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 117-125.	2.3	11
106	Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 235-240.	2.3	8
107	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	2.3	37
108	Synthesis and Fluorescence Characterization of Pteridine Adenosine Nucleoside Analogs for DNA Incorporation. <i>Analytical Biochemistry</i> , 2001, 298, 231-240.	2.4	87

#	ARTICLE	IF	CITATIONS
109	Probe calibration in transient microdialysis in vivo. <i>Pharmaceutical Research</i> , 2001, 18, 361-366.	3.5	33
110	Real-Time Fluorescence Assay for O6-Alkylguanine-DNA Alkyltransferase. <i>Analytical Biochemistry</i> , 2000, 281, 216-222.	2.4	31
111	Effect of Fluconazole on the Pharmacokinetics of Doxorubicin in Nonhuman Primates. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1100-1101.	3.2	14
112	The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex TM) in a nonhuman primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 439-443.	2.3	26
113	Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 464-468.	2.3	59
114	A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection. <i>Pediatrics</i> , 1998, 101, 335-343.	2.1	101
115	A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection. <i>Pediatrics</i> , 1998, 102, 101-109.	2.1	76
116	Fluorescence Properties of Pteridine Nucleoside Analogs as Monomers and Incorporated into Oligonucleotides. <i>Analytical Biochemistry</i> , 1997, 244, 86-95.	2.4	156
117	Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. <i>Biochemical Pharmacology</i> , 1996, 51, 1649-1659.	4.4	23
118	A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. <i>Investigational New Drugs</i> , 1995, 13, 337-342.	2.6	4
119	Incorporation of a fluorescent guanosine analog into oligonucleotides and its application to a real time assay for the HIV-1 integrase 3' processing reaction. <i>Nucleic Acids Research</i> , 1995, 23, 2872-2880.	14.5	91
120	Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. <i>Journal of the Neurological Sciences</i> , 1995, 129, 13-18.	0.6	12
121	Intrathecal administration of topotecan in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 121-124.	2.3	57
122	The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1994, 18, 805-810.	0.8	55
123	Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1994, 125, 142-146.	1.8	22
124	Pharmacokinetics of PEG-l-asparaginase and plasma and cerebrospinal fluid-l-asparagine concentrations in the rhesus monkey. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 310-314.	2.3	31
125	Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. <i>Investigational New Drugs</i> , 1993, 11, 135-140.	2.6	7
126	Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the Rhesus monkey. <i>Investigational New Drugs</i> , 1993, 11, 255-261.	2.6	2

#	ARTICLE	IF	CITATIONS
127	Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. <i>Biochemical Pharmacology</i> , 1993, 45, 1493-1501.	4.4	12
128	Desulfuration of 6-mercaptopurine. <i>Biochemical Pharmacology</i> , 1993, 46, 1627-1636.	4.4	5
129	Intrathecal 5-fluorouracil in the rhesus monkey. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 31, 127-130.	2.3	3
130	A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 155-157.	2.3	5
131	Current Pharmacological Treatment Approaches to Central Nervous System Leukaemia. <i>Drugs</i> , 1991, 41, 702-716.	10.9	29
132	High-performance liquid chromatographic method for the analysis of 2â€²,3â€²-dideoxycytidine in human plasma. <i>Biomedical Applications</i> , 1990, 532, 442-444.	1.7	5
133	A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 343-344.	2.3	27
134	High-performance liquid chromatographic method for analysis of 2â€²,3â€²-dideoxyinosine in human body fluids. <i>Biomedical Applications</i> , 1990, 526, 69-75.	1.7	23
135	A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infusion schedule. <i>Investigational New Drugs</i> , 1990, 8, 159-66.	2.6	9
136	Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. <i>Investigational New Drugs</i> , 1990, 8, 181-2.	2.6	4
137	Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1990, 117, 980-985.	1.8	106
138	Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1990, 117, 799-808.	1.8	89
139	Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1989, 114, 880-884.	1.8	78
140	Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. <i>Journal of Pediatrics</i> , 1988, 112, 996-999.	1.8	25
141	Fluconazole Penetration into Cerebrospinal Fluid: Implications for Treating Fungal Infections of the Central Nervous System. <i>Journal of Infectious Diseases</i> , 1988, 157, 178-179.	4.0	176
142	Folate and Methotrexate Polyglutamate Tissue Levels in Rhesus Monkeys Following Chronic Low-Dose Methotrexate. <i>Cancer Drug Delivery</i> , 1987, 4, 25-31.	0.7	20
143	Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. <i>Pain</i> , 1987, 30, 339-348.	4.2	14
144	The Influence of Route of Administration on the Hepatic Uptake of Methotrexate. <i>Cancer Drug Delivery</i> , 1986, 3, 239-242.	0.7	2

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetic Drug Interactions of Commonly Used Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 1986, 11, 223-235.	3.5	76
146	The Effect of Amitriptyline on the Central Nervous System Penetration of Methotrexate. <i>Cancer Drug Delivery</i> , 1986, 3, 219-222.	0.7	3
147	Influence of Food Intake on Bioavailability of Oral 6-Mercaptopurine in Children with Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 1986, 3, 319-324.	0.8	46
148	Clinical Pharmacokinetics of Commonly Used Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 1983, 8, 202-232.	3.5	91